BERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE AT ERA-EDTA VIRTUAL CONGRESS 2021
Bergen, Norway, 7 June 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to present preclinical data on its first-in-class, fully humanised, therapeutic anti-AXL function blocking monoclonal antibody, tilvestamab, in chronic kidney disease at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress. This preclinical study was conducted to characterise AXL as a target in chronic kidney disease (CKD) and to investigate the